151 related articles for article (PubMed ID: 30503850)
1. Discovery of a novel cathepsin inhibitor with dual autophagy-inducing and metastasis-inhibiting effects on breast cancer cells.
Yuan L; Liu J; He W; Bao Y; Sheng L; Zou C; Hu B; Ge W; Liu Y; Wang J; Lin B; Li Y; Ma E
Bioorg Chem; 2019 Mar; 84():239-253. PubMed ID: 30503850
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel cathepsin inhibitors with potent anti-metastatic effects in breast cancer cells.
Yuan L; Sheng L; He W; Zou C; Hu B; Liu J; Ge W; Liu Y; Wang J; Ma E
Bioorg Chem; 2018 Dec; 81():672-680. PubMed ID: 30253340
[TBL] [Abstract][Full Text] [Related]
3. ASPER-29 suppresses the metastasis of pancreatic cancer cells by dual inhibition of cathepsin-L and cathepsin-S.
Yuan L; Zhao J; Zhao S; Dong T; Dong R; Liu D; Ma E; Li Y
Chem Biol Interact; 2022 Feb; 353():109811. PubMed ID: 35016848
[TBL] [Abstract][Full Text] [Related]
4. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.
Wilder CL; Walton C; Watson V; Stewart FAA; Johnson J; Peyton SR; Payne CK; Odero-Marah V; Platt MO
Int J Biochem Cell Biol; 2016 Oct; 79():199-208. PubMed ID: 27592448
[TBL] [Abstract][Full Text] [Related]
5. SAR studies of some acetophenone phenylhydrazone based pyrazole derivatives as anticathepsin agents.
Raghav N; Singh M
Bioorg Chem; 2017 Dec; 75():38-49. PubMed ID: 28915464
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel asperphenamate derivatives.
Liu Q; Li W; Sheng L; Zou C; Sun H; Zhang C; Liu Y; Shi J; Ma E; Yuan L
Eur J Med Chem; 2016 Mar; 110():76-86. PubMed ID: 26807546
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer cells.
Huang H; Zhang Y; Xu X; Liu Y; Zhao J; Ma L; Lei J; Ge W; Li N; Ma E; Li Y; Yuan L
Bioorg Med Chem Lett; 2023 Jan; 80():129087. PubMed ID: 36427655
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel and selective cathepsin L inhibitor with anti-metastatic ability in vitro and in vivo against breast cancer cells.
Li Y; Ai X; Zou C; Liu Y; Ma L; Men J; Liu D; Sheng L; Ruan X; Liu H; Li W; Ma E; Yuan L
Bioorg Chem; 2021 Oct; 115():105256. PubMed ID: 34426153
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.
Parker EN; Song J; Kishore Kumar GD; Odutola SO; Chavarria GE; Charlton-Sevcik AK; Strecker TE; Barnes AL; Sudhan DR; Wittenborn TR; Siemann DW; Horsman MR; Chaplin DJ; Trawick ML; Pinney KG
Bioorg Med Chem; 2015 Nov; 23(21):6974-92. PubMed ID: 26462052
[TBL] [Abstract][Full Text] [Related]
10. Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer.
Xu T; Zhang J; Yang C; Pluta R; Wang G; Ye T; Ouyang L
Eur J Med Chem; 2021 Jul; 219():113424. PubMed ID: 33862514
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.
Baek KH; Karki R; Lee ES; Na Y; Kwon Y
Bioorg Chem; 2013 Dec; 51():24-30. PubMed ID: 24095934
[TBL] [Abstract][Full Text] [Related]
12. Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.
Kerns JK; Nie H; Bondinell W; Widdowson KL; Yamashita DS; Rahman A; Podolin PL; Carpenter DC; Jin Q; Riflade B; Dong X; Nevins N; Keller PM; Mitchell L; Tomaszek T
Bioorg Med Chem Lett; 2011 Aug; 21(15):4409-15. PubMed ID: 21733692
[TBL] [Abstract][Full Text] [Related]
13. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro antitumor activity of asperphenamate derivatives as autophagy inducer.
Yuan L; Li Y; Zou C; Wang C; Gao J; Miao C; Ma E; Sun T
Bioorg Med Chem Lett; 2012 Mar; 22(6):2216-20. PubMed ID: 22361137
[TBL] [Abstract][Full Text] [Related]
15. A novel cathepsin L inhibitor prevents the progression of idiopathic pulmonary fibrosis.
Yuan L; Zou C; Ge W; Liu Y; Hu B; Wang J; Lin B; Li Y; Ma E
Bioorg Chem; 2020 Jan; 94():103417. PubMed ID: 31744600
[TBL] [Abstract][Full Text] [Related]
16. Chalcones, semicarbazones and pyrazolines as inhibitors of cathepsins B, H and L.
Raghav N; Kaur R
Int J Biol Macromol; 2015 Sep; 80():710-24. PubMed ID: 26193682
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin L mediates resveratrol-induced autophagy and apoptotic cell death in cervical cancer cells.
Hsu KF; Wu CL; Huang SC; Wu CM; Hsiao JR; Yo YT; Chen YH; Shiau AL; Chou CY
Autophagy; 2009 May; 5(4):451-60. PubMed ID: 19164894
[TBL] [Abstract][Full Text] [Related]
18. Effects of novel human cathepsin S inhibitors on cell migration in human cancer cells.
Tsai JY; Lee MJ; Chang MD; Wang HC; Lin CC; Huang H
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):538-46. PubMed ID: 24083411
[TBL] [Abstract][Full Text] [Related]
19. Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.
Frizler M; Schmitz J; Schulz-Fincke AC; Gütschow M
J Med Chem; 2012 Jun; 55(12):5982-6. PubMed ID: 22686657
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.
Anantaraju HS; Battu MB; Viswanadha S; Sriram D; Yogeeswari P
Mol Divers; 2016 May; 20(2):521-35. PubMed ID: 26563150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
